A "Done-For-You" Tech-Enabled Consulting Deliverable

Unlike competitors such as Citeline or H1 that sell DIY database subscriptions and force internal teams to figure out complex demographic math, Augmentios provides a full-service deliverable. Sponsors simply provide their clinical protocol, and the platform hands back a finalized, mathematically flawless Diversity Action Plan (DAP) in 7 days.

Sponsor Control and Transparent Security Framework

Augmentios is explicitly designed as a specialized "Regulatory Engine," keeping the Regulatory Scientist fully in control rather than forcing them to trust a generic AI "black box". The platform features an intelligent WYSIWYG (What You See Is What You Get) interface and live preview that uses active, declarative logic to flag specific operational and budget inputs in red for mandatory sponsor review. This transparent architecture ensures the sponsor maintains complete control, oversight, and enterprise rigor over the final FDA submission.

Mathematical Certainty Over Historical Bias

Legacy strategy firms and CROs rely heavily on "Real-World Data" (RWD) like historical insurance claims and electronic health records, which merely predict the past and replicate existing systemic healthcare inequities. Augmentios relies on programmatic, forward-looking FDA census epidemiology to map the true incidence of the disease, telling sponsors exactly where the FDA demands they go to successfully meet their FDORA mandates.

Eliminating the CRO Conflict of Interest

Large CROs often push sponsors toward their own existing site networks, and when those fail to hit diversity targets, they upcharge the sponsor with million-dollar logistical band-aids like decentralized trial networks, traveling home nurses, or mass-market radio ads. Augmentios is completely network-agnostic and operates on a flat fee. By finding the statistically optimal geographic sites on Day 1, Augmentios ensures the diverse patients are already in the waiting room, protecting sponsors from expensive, mid-trial rescue change orders.

Unmatched ROI and Accelerated Workflows

The DAPORT platform dramatically accelerates regulatory execution, reducing over 40 hours of manual medical writing to just 30 to 60 minutes to generate a 22-part FDA-compliant DAP. By mathematically preventing Refusals to File or End-of-Phase 2 clinical holds, Augmentios eliminates the risk of operational burn rates and lost peak revenue that can cost a sponsor between $600,000 and $8 million per day.

Elite Clinical Leadership and the "Founder Moat"

Unlike generic tech startups or disconnected software developers, Augmentios is led by Natalie Yeadon, a successfully exited serial founder with over 30 years of operational clinical leadership. With a proven track record of building and scaling a global tech platform for Top-20 Pharma clients, and direct experience commercializing blockbuster therapeutics like Herceptin® and IRESSA®, the company is driven by deep domain expertise. This ensures the platform is architected with true clinical governance and commercial understanding, perfectly aligning with the high-stakes needs of Chief Medical Officers.